In the third section of this year’s Generics Bulletin Top 50, a handful of new entrants make their way into the bottom of the rankings, while some volatility is seen among longstanding ranking companies.
After the first part of this year’s Generics Bulletin Top 50 showed upheaval among the top 10 leading off-patent companies and the second part demonstrated movement among the mid-table players (see sidebar), this third and final section of the ranking sees a handful of new entrants making their way into the bottom of the chart, while others exit altogether.
Leading off the third table, we see India’s Biocon climbing from 35th to 31st position in our ranking, ahead of...
This article compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.
In the third instalment of this year’s Generics Bulletin Top 50, we look at some of the firms that have been eliminated from the bottom of our table as others have entered the picture.
In the second part of Generics Bulletin’s Top 50, we see some companies rising up the rankings of generics and biosimilars players worldwide, passing others that are moving in the opposite direction.
Polpharma has struck a deal with MSN Laboratories that will see the Polish generics player distribute the Indian firm’s hospital portfolio in Poland.
Following the FDA’s approval of A 150mg version of Accord’ Herceptin biosimilar, the US agency has now greenlit a higher 400mg strength version of the rival.
